Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo was ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial intelligence (AI) partnership aimed at discovering and developing up to 20 ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and AI.

Novo Nordisk NOVO.B2.14%increase; green up pointing triangle expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human ...

8 January 2025 – Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes ...

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...

Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to expand their existing collaboration to discover and develop new treatments ...